-
Patent Agency Ranking
公开(公告)号：US12122827B2
公开(公告)日：2024-10-22
申请号：US18307477
申请日：2023-04-26
Applicant: Asher Biotherapeutics, Inc.
Inventor： Yik Andy Yeung , Renee L. Greer , Henry C. Nguyen , David Liu , Byong Kang , Ivana Djuretic
CPC classification number: C07K16/244 , A61P35/00 , C07K14/54 , C07K16/2815 , C07K16/40 , A61K38/00 , A61K2039/505 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/565 , C07K2317/64 , C07K2317/92 , C07K2319/30 , C07K2319/33 , C07K2319/74
Abstract: The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+ T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.
-
公开(公告)号：US20250034242A1
公开(公告)日：2025-01-30
申请号：US18915009
申请日：2024-10-14
Applicant: Asher Biotherapeutics, Inc.
Inventor： Yik Andy Yeung , Renee L. Greer , Henry C. Nguyen , David Liu , Byong Kang , Ivana Djuretic
Abstract: The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+ T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.
-
公开(公告)号：US12024559B2
公开(公告)日：2024-07-02
申请号：US17508804
申请日：2021-10-22
Applicant: Asher Biotherapeutics, Inc.
Inventor： Yik Andy Yeung , Ivana Djuretic , Paul Bessette , Wei Chen , Sherman Michael Chin , Kelly Dare Moynihan , Henry C. Nguyen , Irene Ni , Danielle C. Pappas , Terrence Park
CPC classification number: C07K16/2815 , A61K38/2013 , A61K47/65 , A61K47/6849 , A61P31/12 , A61P35/00
Abstract: Provided herein are anti-CD8 antigen binding molecules and fusion polypeptides comprising the CD8 antigen binding molecules for selectively modulating the function of CD8+ T cells over other immune cells. In addition, the present disclosure also provides polynucleotides encoding the disclosed antigen binding molecules and fusion polypeptides, and vectors and host cells comprising such polynucleotides. The present disclosure further provides methods for producing the antigen binding molecules and fusion polypeptides, pharmaceutical compositions comprising the same, and uses thereof.
-
公开(公告)号：US20230357343A1
公开(公告)日：2023-11-09
申请号：US18307477
申请日：2023-04-26
Applicant: Asher Biotherapeutics, Inc.
Inventor： Yik Andy Yeung , Renee L. Greer , Henry C. Nguyen , David Liu , Byong Kang , Ivana Djuretic
CPC classification number: C07K14/54 , C07K16/40 , C07K16/2815 , A61P35/00 , C07K2319/33 , C07K2317/24 , C07K2317/92 , C07K2319/30 , A61K2039/505
Abstract: The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+ T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.
-
公开(公告)号：US20230340104A1
公开(公告)日：2023-10-26
申请号：US18308338
申请日：2023-04-27
Applicant: Asher Biotherapeutics, Inc.
Inventor： Yik Andy Yeung , Renee L. Greer , Henry C. Nguyen , David Liu , Byong Kang , Ivana Djuretic
IPC: C07K16/24
CPC classification number: C07K16/244 , C07K2319/74 , C07K2317/51 , C07K2317/515 , C07K2317/565 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/64
Abstract: The present disclosure provides methods and compositions comprising IL-21 polypeptides, targeted cytokine construct that selectively activates target immune cells (e.g., CD8+ T cells) over other immune cell types. The cytokine of the present disclosure can further comprise mutations that alter its charge distribution to improve its half-life within the blood.
-
-
-
-
Search Results
5
records
(took 0.033 seconds)
